Effect of systemic B-type natriuretic peptide on cardiac vagal motoneuron activity.
Intravenous B-type natriuretic peptide (BNP) enhances the bradycardia of reflexes from the heart, including the von Bezold-Jarisch reflex, but its site of action is unknown. The peptide is unlikely to penetrate the blood-brain barrier but could act on afferent or efferent reflex pathways. To investigate the latter, two types of experiment were performed on urethane-anesthetized (1.4 g/kg iv) rats. First, the activity was recorded extracellularly from single cardiac vagal motoneurons (CVMs) in the nucleus ambiguus. CVMs were identified by antidromic activation from the cardiac vagal branch and by their barosensitivity. Phenyl biguanide (PBG), injected via the right atrium in bolus doses of 1-5 mug to evoke the von Bezold-Jarisch reflex, caused a dose-related increase in CVM activity and bradycardia. BNP infusion (25 pmol.kg(-1).min(-1) iv) significantly enhanced both the CVM response to PBG (n = 5 rats) and the reflex bradycardia, but the log-linear relation between those two responses over a range of PBG doses was unchanged by BNP. The reflex bradycardia was not enhanced in five matched time-control rats receiving only vehicle infusions. In five other rats the cervical vagi were cut and the peripheral right vagus was stimulated supramaximally at frequencies of 1-20 Hz. The bradycardic responses to these stimuli were unchanged before, during, and after BNP infusion. We conclude that systemic BNP in a moderate dose enhances the von Bezold-Jarisch reflex activation of CVM, in parallel with the enhanced reflex bradycardia. That enhancement is due entirely to an action before the vagal efferent arm of the reflex pathway.
Toader
E
E
Department of Physiology, Centre National de la Recherche Scientifique UMR 5123, 8 Rue R Dubois, 69622 Lyon-Villeurbanne, France.
McAllen
R M
RM
Cividjian
A
A
Woods
R L
RL
Quintin
L
L
D000200:Action Potentials; D000818:Animals; D017704:Baroreflex; D001645:Biguanides / Q000494:pharmacology; D001919:Bradycardia / Q000378:metabolism* / Q000503:physiopathology; D004305:Dose-Response Relationship, Drug; D004525:Efferent Pathways / Q000378:metabolism; D004558:Electric Stimulation; D006321:Heart / Q000294:innervation*; D006339:Heart Rate / Q000187:drug effects; D007262:Infusions, Intravenous; D008297:Male; D009046:Motor Neurons / Q000187:drug effects / Q000378:metabolism*; D009419:Nerve Tissue Proteins / Q000008:administration & dosage / Q000378:metabolism*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013997:Time Factors; D014628:Vagotomy; D014630:Vagus Nerve / Q000187:drug effects / Q000378:metabolism*
D001645:Biguanides; D009419:Nerve Tissue Proteins; C073021:brain natriuretic peptide-45; C008846:phenyl biguanide